NCT05311618 2024-04-01Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsNGM Biopharmaceuticals, IncPhase 1 Unknown71 enrolled
NCT02758587 2018-03-19Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)NHS Greater Glasgow and ClydePhase 1/2 Unknown59 enrolled